Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

Mar 28, 2024 16:05 ET
ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer
ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer VELDHOVEN, the Netherlands, March 28, 2024 – ASML Holding NV (ASML) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC to...
Mar 28, 2024 16:05 ET
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Absci management is scheduled to present on...
Mar 28, 2024 16:05 ET
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the full year ended December 31, 2023 and...
Mar 28, 2024 16:05 ET
Acuity Brands Declares Quarterly Dividend
The Board of Directors of Acuity Brands, Inc. (NYSE: AYI; "Company") today declared a quarterly dividend of 15 cents per share. The dividend is payable on May 1, 2024, to shareholders of record on April 17, 2024. About Acuity Brands Acuity...
Mar 28, 2024 16:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on March 25, 2024, the...
Mar 28, 2024 16:05 ET
ArriVent BioPharma Reports Full Year 2023 Financial Results
ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the full year ended...
Mar 28, 2024 16:05 ET
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023....
Mar 28, 2024 16:05 ET
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated...
Mar 28, 2024 16:05 ET
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced results from a special meeting of stockholders held March 27, 2024. During...
Mar 28, 2024 16:05 ET
CGRA Announces Completion and Publication of 2023 Annual Disclosure
via NewMediaWire -- CGrowth Capital Inc. (OTC: CGRA) is a public holding company for alternative and undervalued assets. The company is sector and industry agnostic and currently consists of two divisions including Mining and Sports Technology. The...
Mar 28, 2024 16:05 ET
Dime Community Bancshares Declares Quarterly Cash Dividend for Common Stock
Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company”) announced that its Board of Directors today declared a quarterly cash dividend of $0.25 per share of Common Stock, payable on April 24, 2024 to common stockholders of record as of April...
Mar 28, 2024 16:05 ET
Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests
Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today it completed an acquisition of mineral interests totaling approximately 1,485 net royalty acres located in two counties in Colorado. The transaction was structured as a...
Mar 28, 2024 16:05 ET
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on...
Mar 28, 2024 16:05 ET
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial...
Mar 28, 2024 16:05 ET
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management...
Mar 28, 2024 16:05 ET
Global-e Announces Filing of Form 20-F for the Fiscal Year Ended December 31, 2023
Global-e Online Ltd. (Nasdaq: GLBE) the leader of global Direct-To-Consumer ecommerce enablement, announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission. The...
Mar 28, 2024 16:05 ET
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year...
Mar 28, 2024 16:05 ET
Leading Proxy Advisory Firms Recommend ContextLogic Stockholders Vote “FOR” Pending Transaction with Qoo10
ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) today announced that proxy advisory firms Institutional Shareholder Services (“ISS”), Glass Lewis and Egan-Jones have all recommended that ContextLogic stockholders...
Mar 28, 2024 16:05 ET
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results...
Mar 28, 2024 16:05 ET
Sharecare announces fourth quarter and full year 2023 financial results and operational highlights
Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter and year ended December 31, 2023. "In my first three months as CEO, I have been...